identifi

A Personalised Approach to Heart Health with

DGx
Cardio Screening

Using NGS



POWERED BY HaystackAnalytics

Precision care for inherited heart disorders

- Informed diagnosis, prognosis and management
- Comprehensive information on genetic variants
- Early detection and risk prediction
- Genetic testing is a key clinical recommendation[1,2]

DGx Cardio Screening covers

Cardiomyopathies (impacts heart muscle)	DCM, RCM, ARVD/C, LGMD, intrinsic, myofibrillar, MYPN-related and PRKAG2-related myopathies
Channelopathies (impacts electrical signalling)	Brugada Syndrome, Familial Long QT syndrome, Short QT, ARVC/D, CPVT, DCM 1E, DCWHK
Aortopathies (impacts aortic blood flow)	Familial TAAD, AOS
Lipidemias (impacts cholesterol metabolism)	Familial hypercholesterolemia
Rare Diseases (underdiagnosed/uncommon diseases impacting heart function)	Syndromic: Barth, Noonan, Ehler Danlos (vascular type), Danon, Emery-Dreifuss muscular dystrophy, Jervell and Lange-Nielsen, Fabry disease, Loeys-Dietz, Marfan, hereditary ATTR amyloidosis, mitochondrial DNA depletion syndrome 12B Non-Syndromic: genetic hearing loss

Benefits of DGx Cardio Screening

Confirms aetiological diagnosis

Enables appropriate surveillance and treatment options

Enables cascade/ predictive testing for family members

DGx Cardio Screening actionables

Medications

Implantable devices

Heart transplant

Prognostication information

Family planning and reproductive choices

Lifestyle management

Who should get tested?

Important for all patients,
Especially those with:

- A family history of sudden cardiac death
- Clinical diagnosis of cardiomyopathies and/or suspected genetic heart diseases
- Inherited conditions like familial hypercholesterolemia
- At risk family members of those identified with genetic causes of cardiomyopathies

Highlights of DGx Cardio Screening

- Comprehensive coverage (78 genes, 10,000 + variants)
- Updated variant databases
- Actionable, interpretable report

References

[1]Musunuru, Kiran, et al. "Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association." Circulation: Genomic and Precision Medicine 13.4 (2020): e000067.

[2]Arbelo, Elena, et al. "2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)." European heart journal 44.37 (2023): 3503-3626.

HaystackLabs

H-22, 23 Akshar Business Park, Sector 25,
Turbhe, Navi Mumbai 400703

+91 88288 31393 identifi@haystackanalytics.in